Yes, Tremfya Treats Plaque Psoriasis
Tremfya (guselkumab) is FDA-approved for moderate-to-severe plaque psoriasis in adults who qualify for systemic therapy or phototherapy.[1] It targets interleukin-23 (IL-23), a cytokine driving psoriasis inflammation, administered as subcutaneous injections every 8 weeks after initial doses.[1]
How Does Tremfya Work for Psoriasis?
Tremfya blocks IL-23, reducing skin plaques, scaling, and itching. Phase 3 trials (VOYAGE 1 and 2) showed 73-91% of patients achieving PASI 90 (90% skin clearance) at week 16, versus 3% on placebo.[2] Long-term data indicate sustained response in over 80% of patients at 4 years.[2]
What Psoriasis Types Does It Cover?
Primarily plaque psoriasis, including scalp and nail involvement. Not approved for guttate, pustular, or erythrodermic psoriasis, though off-label use occurs in some cases.[1]
How Does Tremfya Compare to Other Psoriasis Drugs?
| Drug | Mechanism | Dosing | PASI 90 at Week 16 |
|------|-----------|--------|---------------------|
| Tremfya | IL-23 inhibitor | 100 mg Q8W | 73-91% [2] |
| Skyrizi (risankizumab) | IL-23 inhibitor | 150 mg Q12W | 74-76% [3] |
| Cosentyx (secukinumab) | IL-17A inhibitor | 300 mg Q4W | 71-80% [3] |
| Stelara (ustekinumab) | IL-12/23 inhibitor | 45-90 mg Q12W | 44-61% [3] |
Tremfya matches top biologics in efficacy with convenient dosing.[3]
Common Side Effects and Patient Concerns
Upper respiratory infections (14-19%), headache (5-10%), and injection-site reactions (8-20%). Rare risks include serious infections or malignancies; monitor tuberculosis before starting.[1] Patients report rapid improvement in quality of life, with itch relief in weeks.[2]
Who Makes Tremfya and Coverage Details?
Janssen (Johnson & Johnson) manufactures it. List price ~$6,800 per dose; patient assistance programs reduce costs for eligible uninsured.[4] Covered by most Medicare Part D and commercial insurance for qualifying psoriasis.[4]
When Does Tremfya's Patent Expire?
Key U.S. patents expire 2032-2034, with pediatric exclusivity to 2035. Challenges from Amgen and Samsung Bioepis ongoing; biosimilars unlikely before 2033.[5]
[1]: FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s029lbl.pdf
[2]: Janssen Clinical Data - https://www.tremfya.com/psoriasis/clinical-trial-results
[3]: Comparative Review, J Am Acad Dermatol (2022) - https://doi.org/10.1016/j.jaad.2022.01.045
[4]: GoodRx Pricing - https://www.goodrx.com/tremfya
[5]: DrugPatentWatch - https://www.drugpatentwatch.com/p/tradename/TREMFYA